Kodiak Sciences Aktie

Kodiak Sciences is using its proprietary ABC platform to develop novel biologics to treat serious, vision‑threatening retinal diseases such as wet macular degeneration and diabetic retinopathy. The drugs are intended to allow substantially longer injection intervals of up to six months, reducing patient burden. As a biotech company in the late clinical stage, Kodiak does not yet generate operating revenues but offers significant growth potential if the trials are successful. » More on finanzen.net

Kodiak Sciences has successfully completed the phase-3 DAYBREAK study for Zenkuda and KSI-501. Both agents met the primary endpoint and demonstrated superiority to the standard treatment Eylea. The company is now preparing regulatory filings with the FDA after the results triggered a strong share-price increase. » More on finanzen.net

Kodiak Sciences has initiated the global phase‑3 ALTO study and is recruiting about 910 treatment‑naive and previously treated patients to evaluate KSI‑501 versus aflibercept in diabetic macular edema. The randomized trial has three arms (two KSI‑501 dosing regimens of different intensity and one aflibercept arm) and the primary endpoint is mean change in best‑corrected visual acuity averaged over weeks 48 and 52. Key secondary endpoints include improvement on the Diabetic Retinopathy Severity Scale through week 48; treatment and follow‑up last about 96 weeks. KSI‑501 is a bispecific therapeutic designed to inhibit IL‑6‑mediated inflammation and VEGF‑mediated vascular permeability; the DAYBREAK phase‑3 trial in wet AMD is already recruited, with initial one‑year results expected in September 2026. » More on de.investing.com